Trillium Therapeutics Inc (NASDAQ: TRIL) is having an incredibly strong start to the trading session this morning, and for good reason. The company said that it would be providing updates on two clinical trials at two upcoming scientific conferences. Of course, the news excited investors who are sending the stock on a run for the top. Today, we’ll talk about:
- The coming updates;
- what we’re seeing from TRIL stock as a result; and
- what we’ll be watching for ahead.
TRIL Announces Coming Updates
As mentioned above, Trillium Therapeutics is having a strong start to the trading session this morning after the company said that it would be providing updates on two clinical trials. The trials are centered around the company’s TTI-621 candidate. The candidate is a dual function SIRPaFc IgG1 decoy receptor that targets CD47 and the data will be provided at two upcoming scientific conferences. These conferences include the European Organisation for Research and Treatment of Cancer, Cutaneous Lymphoma Task Force meeting and the 16th Annual Discovery on Target conference.
TRIL said that the presentation at the first meeting will provide investors with an update on the safety and efficacy of the ongoing Phase 1 intratumoral trial of TTI-621. During the trail, the treatment is being assessed in 23 patients with relapsed or refractory mycosis fungoids/Sézary syndrome. 20 of these patients have only received induction therapy consisting of between one and six injections over two weeks. The data show that the treatment was well tolerated and effective, with local lesion responses observed in 89% of patients and 42% of patients exhibiting reductions of 50% or more.
The presentation at the Discovery on Target conference will provide a high level update of the safety and efficacy of the ongoing, multicenter, open-lable Phase 1a/b intravenous trial of TTI-621. Once again the data seems to be promising. While there were adverse events, platlet reductions were shown to be transient and pre-dose platelet levels remained steady throughout the course of the study. Also, clinical activity was achieved at low doses. Higher dose cohorts are currently ongoing.
In a statement, Dr. Yaping Shou, CMO at TRIL, had the following to offer:
These data expand on the observations first presented at ASH 2017, and highlight the potential value of localized delivery of TTI-621 in heavily pre-treated mycosis fungoides/ Sézary syndrome patients… We are particularly encouraged to see reductions in CAILS scores after such a short course of therapy, and the abscopal effect seen in one of the two patients receiving continuation treatment suggest that a longer duration of dosing may offer further opportunity to induce systemic responses.
The above statement was followed up by Dr. Niclas Stiernholm, President and CEO at TRIL. Here’s what he had to offer:
The ability to induce rapid anti-tumor responses through local administration with our potent IgG1-containing Fc fusion protein opens up numerous possibilities, not only in mycosis fungoides but also in many solid tumors. As is the case with other agents targeting the innate immune system, such as STING and TLR agonists, local administration is the route of choice to ensure instant high local drug concentrations at the site of the tumor… We intend to expand the intratumoral program both with respect to additional indications and combination therapies with complementary immunostimulatory therapies, especially those acting downstream of CD47.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dig into the market is that the news leads to moves. In the case of Trillium Therapeutics, the news proved to be overwhelmingly positive. The two presentations coming soon are centered around positive data that further validates the company’s efforts with regard to TTI-621. So, it comes as no surprise that excited investors are sending the stock on a run for the top. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:38), TRIL is trading at $6.40 per share after a gain of $0.47 per share or 8.02% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on TRIL. In particular, we’re interested in following the ongoing development of TTI-621 as the treatment seems to be yielding positive results. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!